Who are Hydroxychloroquine Sulfate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hydroxychloroquine Sulfate, INT230-6, Coartem, Coartem, Qualaquin, Malarone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroxychloroquine-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Hydroxychloroquine Sulfate — Competitive Intelligence Brief

Hydroxychloroquine Sulfate (hydroxychloroquine-pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Immunology.

discontinued Antimalarial Toll-like receptor 9 Immunology Live · refreshed every 30 min

Target snapshot

Hydroxychloroquine Sulfate (hydroxychloroquine-pill) — Sanofi. Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and modulating the immune system to treat autoimmune diseases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Hydroxychloroquine Sulfate TARGET	hydroxychloroquine-pill	Sanofi	discontinued	Antimalarial	Toll-like receptor 9	1955-01-01
Hydroxychloroquine Sulfate	HYDROXYCHLOROQUINE	Advanz	marketed	Antimalarial	Toll-like receptor 9	1955-01-01
INT230-6	INT230-6	Intensity Therapeutics, Inc.	phase 3	TLR9 agonist immunotherapy	TLR9 (Toll-like receptor 9)
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

London School of Hygiene and Tropical Medicine · 6 drugs in this class
Sanofi · 3 drugs in this class
Epicentre · 2 drugs in this class
University of Oxford · 2 drugs in this class
· 2 drugs in this class
Frantz Viral Therapeutics, LLC · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Institut de Recherche pour le Developpement · 1 drug in this class
Centre de Recherche Médicale de Lambaréné · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hydroxychloroquine Sulfate — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxychloroquine-pill. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab